JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, cilt.75, sa.2, ss.133-144, 2020 (SCI-Expanded, Scopus)
BACKGROUND Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C).